|
February 10, 2012
|
| 11:58 EDT |  | AMGN |
|
| 07:10 EDT |  | AMGN |
|
| 06:35 EDT |  | AMGN |
| theflyonthewall.com: | Amgen initiated with an Equal Weight at Morgan Stanley | | :theflyonthewall.com |
|
| 06:18 EDT | | AMGN |
|
|
February 9, 2012
|
| 16:27 EDT | | AMGN |
| theflyonthewall.com: | Leerink's biotech and pharmaceuticals analysts hold a conference call | | Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com |
|
| 10:32 EDT |  | AMGN |
| theflyonthewall.com: | On The Fly: Analyst Downgrade Summary | | Today's noteworthy downgrades include: Diamond Foods (DMND) downgraded to Neutral from Buy at SunTrust...3M Company (MMM) downgraded to Hold from Buy at Deutsche Bank...Sohu.com (SOHU) downgraded to Hold from Buy at Deutsche Bank...Amgen (AMGN) downgraded to Perform from Outperform at Oppenheimer...A123 Systems (AONE) downgraded to Sell from Hold at Wunderlich...iRobot (IRBT) downgraded to Underweight from Neutral at JP Morgan...Federated Investors (FII) downgraded to Underperform from Neutral at Macquarie...CVS Caremark (CVS) downgraded to Neutral from Outperform at Macquarie...DirecTV (DTV) downgraded to Neutral from Outperform at Macquarie...Wright Express (WXS) downgraded to Neutral from Buy at Janney Capital...Boyd Gaming (BYD) downgraded to Equal Weight from Overweight at Barclays...Joy Global (JOYG) downgraded to Hold from Buy at Jefferies...DuPont Fabros (DFT) downgraded to Hold from Buy at Jefferies...DuPont Fabros downgraded to Market Perform from Outperform at Wells Fargo...TripAdvisor (TRIP) downgraded to Hold from Buy at Benchmark Co. :theflyonthewall.com |
|
| 06:15 EDT | | AMGN |
| theflyonthewall.com: | Amgen downgraded to Perform from Outperform at Oppenheimer | | Oppenheimer downgraded Amgen citing a lack of near-term catalysts after an FDA panel voted against recommending approval of Xgeva in bone metastasis prevention. :theflyonthewall.com |
|
|
February 8, 2012
|
| 12:09 EDT |  | AMGN |
|
| 11:41 EDT |  | AMGN |
|
| 10:46 EDT | | AMGN |
|
| 10:41 EDT | | AMGN |
| theflyonthewall.com: | Amgen FDA panel meeting for Xgeva not proceeding well, says Deutsche Bank | | Deutsche Bank believes FDA panel members do not see clinical benefit of Xgeva in non-met high-risk CRPC patients as today's meeting progresses. The firm says panel recommendation for approval to the FDA seems very unlikely. :theflyonthewall.com |
|
|
February 7, 2012
|
| 17:41 EDT | | AMGN |
|
| 07:16 EDT | | AMGN |
| theflyonthewall.com: | Dendreon price target raised to $18 from $16 at Canaccord | | Canaccord said the negative FDA stance on Amgen's (AMGN) XGEVA de-risks its outlook for Dendreon's (DNDN) Provenge. The firm believes Provenge will occupy a disease treatment setting of newly metastatic disease all alone. Shares are Buy rated. :theflyonthewall.com |
|
|
February 6, 2012
|
| 11:15 EDT | | AMGN |
|
| 09:30 EDT | | AMGN |
| theflyonthewall.com: | Amgen downgraded to Sell from Neutral at Lazard Capital | | Price target is $58. :theflyonthewall.com |
|
| 09:00 EDT | | AMGN |
| theflyonthewall.com: | FDA panel unsure if Xgeva study results clinically meaningful, support labeling |
 Subscribe for More Information :theflyonthewall.com |
|
|
February 3, 2012
|
| 06:05 EDT | | AMGN |
| theflyonthewall.com: | Amgen risk/reward attractive into Xgeva panel, says Deutsche Bank | | Deutsche Bank likes the risk/reward on Amgen shares into the February 8 FDA panel discussing Xgeva for the prevention of bone mets in high-risk prostate cancer. The firm sees shares upside potential of $1.50-$3.00 but keeps a Hold rating on the stock. :theflyonthewall.com |
|
|
January 31, 2012
|
| 11:21 EDT | | AMGN |
|
| 09:26 EDT | | AMGN |
| theflyonthewall.com: | Amgen target raised to $80 from $66 at Argus | | Argus believes that Amgen reported solid Q4 results, and the firm reports that sales of the company's new products, Prolia and XGEVA, accelerated sharply last quarter. The firm thinks that the company's outlook is positive and maintains a Buy rating. :theflyonthewall.com |
|
